PARTNERS
Participant's list
Participant Number
Participant name
Participant short name
Country
Institute
Date exit project
1a
MW
Belgium
KULeuven
coordinator
2
JE
Spain
Fundacio IrsiCaixa
contractor
3a
JD
France
INSERM-ENS
contractor
4
JV
Spain
Univ. de Barcelona
contractor
1b
ZD
Belgium
KULeuven
contractor
3b
RB
France
INSERM
contractor
7
AC
Italy
Univ. of Messina
contractor
8
UD
Germany
GSH Frankfurt
contractor
9
GD
France
CNRS-DR13/CRBM
contractor
10
JE
Germany
JWG-Univ. Frankfurt
contractor
11
MG
Russia
Belozerski Institute
contractor
12
NH
United Kingdom
Heriot-Watt Univ.
contractor
13
RK
The Netherlands
Utrecht Univ.
contractor
14
OK
Germany
Univ. of Heidelberg
contractor
15
LK
Hungary
Univ. of Szeged
contractor
16
GM
Italy
IGM-CNR
contractor
17
SM
Italy
Univ. Siena
contractor
18
YM
France
Univ. Louis Pasteur
contractor
19
J-FM
France
CNRS-IDFE
contractor
20
TR
Germany
UKSH Campus Lübeck
contractor
21
IM
Spain
Univ. of Seville
contractor
22
VV
Yugoslavia
Institute Nuclear Sciences VINCA
contractor
23
JV
Spain
Univ. Miguel Hernandez
contractor
24
PV
Switzerland
Ecole Polytechnique Fédérale de Lausanne
contractor
25
NGJ
Sweden
Medivir SA
contractor
26
JCR
France
Hybrigenics SA
contractor
28
HL
The Netherlands
Pepscan Systems B.V.
contractor
*: No EU funding
Participant No.
Principal Scientific Participant
Coworkers
Area of Expertise
Prof. Myriam Witvrouw
Division of Molecular Medicine, Laboratory of Molecular Virology and Drug Discovery
KULeuven, Belgium
Peter Bogaerts (management)
Ann Nijs (left)
Barbara Van Remoortel
Leen Hombrouck
Nam-Joo Van der VekenLeen Luyts (administration)
Evaluation of HIV inhibitors (all targets) in HIV replication assays. Antiviral resistance. Preclinical pharmacokinetic evaluation (mice, rabbit) of anti-HIV drugs.
Dr. José A. Esté, Senior Res.
Retrovirology Lab., Fundació irsiCaixa,
Hospital Germans Trias i Pujol,
Badalona, Spain
Dr. Miguel A. Martínez*
Dr. Julià Blanco*
Dr. Cecilia Cabrera*
Dr. Bonaventura Clotet*
Mercedes Armand-Ugon
Gemma Moncunill
Screening of anti-HIV activiy against wild and MDR strains. Evaluation of activities or toxicities in ex vivo limphoid tissues. Mechanism of action of antiviral drugs. Biotechnology of fusion inhibitors. Phase I clinical trials
Prof. Jean-Luc Darlix
LaboRetro, Dept. of Human Virology
Lyon, France
Dr. Andrea Cimarelli
Dr. Théophile Ohlmann
Dr. Pascal Leblanc
Dr. Delphine Muriaux
Caroline Goujone
Cécile Guichard
Nucleocapsid protein implications in proviral DNA synthesis and integration. NC, as Gag, implications in the regulation of translation and HIV assembly. NC-PrPc interactions and impact on HIV assembly. Dvpt of anti-NC inhibitors.
Prof. Dr. Jaume Vilarrasa
Dept. Química Orgànica, Univ. Barcelona
Barcelona, Spain
Prof. Jaume Farràs,
Prof. Xavier Ariza,
Dr. Anna M. Costa
Computational chemistry. Design and synthesis of novel generation RT and IN inhibitors. Nucleoside & nucleotide transformations. Enantiopure antibiotics, antivirals and antitumorals.
Prof. Zeger Debyser
Laboratory for Molecular Virology and genetherypy, Division of Molecular Medicine
& Laboratory for Biomolecular Dynamics, Department of ChemistryKULeuven, Belgium
Prof. Yves Engelborghs *
Dr. Jo Vercammen *
Dr. Frauke Christ *
K. Busschots*
Arnout Voet*
Brigitte Verheyden* (secr.)
Evaluation of integrase inhibitors in enzym. and replication assays. Biophysical assays for HIV integrase. Genomics and proteomics. Modeling and docking of lead inhibitors.
Dr. Richard Benarous
Director Department of Infectious Diseases Institut Cochin,
Paris, France
Dr. Stephane Emiliani,
Dr. Clarisse Berlioz-Torrent,
Dr. Corinne Besnard-Guerin
LangXia Liu
Cellular partners of integrase and other HIV-1 proteins. Requirement of these proteins for HIV-replication, by siRNAs based assays. Mapping of interacting domains. Screening assays for HIV-1 inhibitors.
Prof. Alba Chimirri
Dip. Farmaco Chimico
Università degli Studi di Messina
Messina, Italy
Dr. Maria Letizia Barreca*
Dr. Angela Rao*
Prof. Maria Teresa Zappalà*
Cristina Gurnari*
Stefania Ferro*
Laura De Luca*
I. Sacca (secr.)
Structural and functional analysis of HIV proteins (IN) by computational techniques. Rational drug design, synthesis and discovery of anti-HIV agents.
Dr. Ursula Dietrich
Georg-Speyer-Haus
Institute for Biomedical Research
Frankfurt, Germany
Dr. Dorothee von Laer,
Dr. Xavier Dervillez,
Alexandra Hüther
Felix Hermann
Characterization of viral and cellular entry domains by the phage display technology. Entry inhibitors. Expression of fusion inhibitors for gene therapy. Identification of epitopes.
Dr. Gilles Divita
Centre de Rech. Biochimie Macromoléculaire
Montpellier, France
Dr. May Morris,
Dr. C. Gondeau,
Dr. M. L. Hourdou
Reverse transcriptase and integrase dimerization inhibitors. Vectorization, gene delivery, mechanism of action. Carrier systems for drug delivery.
Prof. Dr. Joachim Engels
Institut für Organische Chemie
Johann Wolfgang Goethe-Universität
Frankfurt, Germany
Dr. Andreas Zimmer,
Dr. Valentin Wittmann
Anti-HIV ribozymes. Antisense oligonucleotides. RNAs. Biopolymers of carrier systems for RNA ligands
Dr. Marina Gottikh
Belozersky Institute of Physico-Chemical Biology, Moscow State University
Moscow, Russia
Dr. Elena Romanova,
Dr. Eugenii Volkov
J. Agapkina
H. Smolov
T. Prikazchirova
Synthesis of oligonucleotides. Modification of nucleobases, sugars and phosphates, Study of IN–DNA interactions using modified synthetic analogues of retroviral DNA.
Dr. Nicola M. Howarth,
Department of Chemistry,
Heriot-Watt University, Riccarton,
Edinburgh, UK
Dr. Michael G. Thomas
K.M.P. Collart
K.F. Adembambo*
M. Biyani*
Design and synthesis of oligonucleotide mimics for antisense/antigene applications. Development of novel nucleic acid biosensors.
Prof. Dr. Robert Kaptein
Utrecht University
Bijvoet Center for Biomolecular Research
The Netherlands
Prof. Rolf Boelens,
Dr. Alexandre Bonvin,
Dr. Gert Folkers,
Dr. Anna Hotze
Dr. Rainer Wechselberger
Structural studies of proteins by NMR spectroscopy. HIV integrase domains. DNA-binding proteins and protein-DNA interaction
Dr. Oliver T. Keppler
Department of Virology
University of Heidelberg
Heidelberg, Germany
oliver_keppler@med.uni-heidelberg.deDr. Ina Allespach
Dr. Lismarie Schüller
Evaluation of antiviral compounds in a transgenic rat model of HIV infection.
Dr. Lajos Kovacs, Senior Researcher
Nucleic Acids Laboratory
University of Szeged
Szeged, Hungary
Dr. Miklos Hornyak,
Dr. Zoltan Kupihar
Ms. Györgyi Ferenc
Ms. Petra Pàdàr
Peptide nucleic acids (PNAs). PNA–peptide and PNA–oligonucleotide conjugates. Methodical developments in oligonucleotide synthesis and applications. Functionalization of nucleobases.
Dr. Giovanni Maga, Researcher - CNR
Istituto di Genetica Moleculare
IGM-CNR
Pavia, Italy
Dr. Federico Focher
Dr. Silvio Spadari,
Dr. Raffaella Franez
Dr. Reynel Cancio
Mechanism of action of anti-RT drugs (NRTIs and NNRTIs). Molecular basis of drug resistance.
Biotechnology. HIV-1 RT cloned gene. Recombinant enzymes.
Prof. Silvio Massa
Dip. Farmaco Chimico Tecnologico
Università degli Studi di Siena
Siena, Italy
Dr. Elena Petricci
Mr. Marco Radi
Dr. Fabrizio Manetti,
Dr. Claudia Mugnaini
Dr. Michela Renzulli
Miss. Cristina Tintori
Mr. Cesare Bernardini
Mr. Andrea Togninelli
NNRTI drug synthesis and biotechnology. Molecular modeling of receptor-pharmacophore interactions. Bioinformatics.
Prof. Yves Mély
Lab de Pharmacologie et Physico-Chimie
CNRS, Faculté de Pharmacie
Université Louis Pasteur
Strasbourg, France
Dr Etienne Piémont
Dr. Emmanuel Schaub
Dr. Chinnappan Raja
Dr. H. de Rocquignuy
Analysis of the interaction of NCp7 with nucleic acids and Zn 2+ using fluorescence based methods. Molecular mechanism of NCp7 chaperone activity. Development of anti-NC inhibitors .
Dr. Jean-François Mouscadet
CNRS UMR8113
École Normale Supérieure de Cachan,
Cachan, France
Dr. Jean-Claude Brochon
Dr. Marc Le Bret
Dr. Malcolm Buckle
Dr. Eric Deprez
Dr. Elvine Guiot
Dr. Olivia Delelis
Design and in vitro evaluation of INIs (modeling, docking, and enzymatic assays). Oligonucleotidic inhibitors of the IN–DNA complex. Recombinant enzymes. Time-resolved methods for enzyme biophysical studies.
Prof. Tobias Restle
Universitätsklinikum Schleswig-Holstein
Campus Lübeck
Lübeck, Germany
Prof. Dr. Georg Sczakiel
RT dimerization inhibitors. Aptamers, RNAi, viral vectors, carrier systems for drug delivery, fluorescence-based screening systems, molecular genetics, transient enzyme kinetics and physiology.
Prof. Inmaculada Robina
Departamento de Química Orgánica
Fac. de Química, Universidad de Sevilla
Sevilla, Spain
Prof. Francisca Cabrera,
Prof. José Luís Espartero,
Dr. Antonio J. Moreno,
Dr. Ana T. Carmona,
Dr. Yolanda Vera
Glycomimetics. Synthesis of HIV entry inhibitors. Carbohydrate-peptide conjugates. V3 loop analogs of gp120.
Dr. Veljko Veljkovic
Center for Multidisciplinary Research
Institut of Nuclear Sciences Belgrade Belgrade, Serbia/Yugoslavia
Dr. Jelena Prljic,
Dr. Nevena Veljkovic,
Dr. Vesna Skerl,
Prof. Djordje Jevtovic
Design of peptides mimicking the C2 region of HIV-1 gp120 for therapy and prevention of HIV-caused diseases. Clinical trials.
Dr. José Villalaín, Senior Res.
Molecular and Cellular Biology Institute
Elche-Alicante, Spain
Jaime Guillén Structure and interaction of gp41 with biomembranes. Mechanism of membrane fusion; biophysical studies (2DIR, DSC, ITC, fluorescence, NMR of solids). Gp41-induced membrane fusion inhibitors.
Prof. Dr. Pierre Vogel
École Polytechnique Féd. de Lausanne
Lausanne, Switzerland
Dr. Florence Popowycz,
Dr. Robert Lysek,
Oligosaccharide mimetics. Glycopeptides as epitope analogs with enhanced immunogenicities. New vaccines against AIDS. Enzymatic studies. Cell language and sociology.
Dr. Nils Gunnar Johansson
MEDIVIR AB
Huddinge, Sweden
Prof. Bertil Samuelsson
Dr. Lotta Vrang
Non-nucleoside reverse transcriptase inhibitors (NNRTIs). X-ray data on MIV-150 to guide modelling and design. Provision of selected and targeted compounds to WP1, WP2 and WP5 for assay. In vitro DMPK for WP1/2/3. Industrial expertise on discovery, development and clinical studies of anti-HIV compounds.
Dr. Jean-Christophe Rain
HYBRIGENICS S.A
Paris, France
Dr. Emmanuelle Vanméris
Dr. Gaëlle Conan
Dr. Philippe Desmoucelle
Identification of cellular targets of HIV-1 by two-hybrid screens.
Mapping of interacting domains. Screening of HIV-1 inhibitors by isolation of peptidic ligands of these partners and/or selection of chemicals inhibiting host-virus interactions.
Pepscan Systems B.V.
Dr. Hans Langendijck
Dr. Peter Timmerman
Dr. Nicole Kriek
Mr. Evert van Dijck
Mr. Drohpatie Parohi
Mr. Gerrit Hof
Design, preparation and screening of synthetic peptide libraries and subsequentely of the reconstruction of sites as relatively simple and small peptide-like molecules
École Normale Supérieure de Lyon
Università degli Studi di Messina
Lomonosov Moscow State University
Ruprecht-Karls
Universität Heidelberg
University of Szeged
Università di Siena
École Normale Supérieure de Cachan
Universitätsklinikum Schleswig-Holstein Campus Lübeck
Centre Nationale de la Recherche Scientifique
Institut national de la santé et de la reserche médicale
Consiglio Nationale delle Ricerche
Institute for Nuclear Sciences 'Vinca'
Copyright © Katholieke Universiteit Leuven | reacties op de inhoud: Peter Bogaerts
Realisatie: Bruno Hoste/Peter Bogaerts | Laatste wijziging:
29-05-2007
URL: http://www.kuleuven.be/molvirgen/projects/trioh/partnerstr.htm
